15 patents
Utility
Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF
16 Jan 24
The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist.
Kevin Peters
Filed: 10 Dec 20
Utility
Methods of Treating Intraocular Pressure with Activators of TIE-2
14 Dec 23
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.
Kevin PETERS
Filed: 21 Apr 23
Utility
Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
14 Nov 23
Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof.
Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis
Filed: 7 Feb 20
Utility
Formulations of TIE-2 Activators and Methods of Use Thereof
4 May 23
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTPβ.
Kevin PETERS
Filed: 15 Jun 22
Utility
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
4 May 23
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
Kevin PETERS, Michael Allen FLYNN
Filed: 27 May 22
Utility
Injector for Delivering Implants
6 Apr 23
An injector includes a push rod, a magazine tube, a gate, a cannula and an actuator.
Michelle HOWARD-SPARKS, Said SAIM, Amelia SCHILLING, Dario PAGGIARINO, Nathan ROLLINS, Evan Hunter WILLIAMS, Phillip HALBERT, Daniel P. SMITH, Michael W. METZ, Dustin GAIDOS, Joshua MARTIN
Filed: 3 Oct 22
Utility
Bioerodible Drug Delivery Devices
30 Mar 23
This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment.
Hong GUO, Jianbing CHEN
Filed: 4 Oct 22
Utility
Small molecule activators of Tie-2
28 Mar 23
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.
John M. Janusz
Filed: 28 Oct 20
Utility
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
1 Dec 22
The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis.
Jeffrey Lyle Gray, Kande K.D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
Filed: 25 Feb 22
Utility
Compositions, Formulations and Methods for Treating Ocular Diseases
1 Sep 22
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.
Kevin PETERS, Robert SHALWITZ, John JANUSZ, Alexander SMITH
Filed: 3 Mar 22
Utility
Formulations of Tie-2 activators and methods of use thereof
16 Aug 22
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTPβ.
Kevin Peters
Filed: 23 Jun 20
Utility
Bioerodible Drug Delivery Devices
30 Jun 22
This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment.
Hong Guo, Jianbing CHEN
Filed: 17 Mar 22
Utility
Bioerodible Ocular Drug Delivery Insert and Therapeutic Method
2 Jun 22
This invention relates to implantable bioerodible inserts for delivering an active pharmaceutical ingredient to the eye.
Said SAIM, Michelle SPARKS, Dario PAGGIARINO, Basel KARZOUN
Filed: 14 Feb 22
Utility
Tie-2 activators targeting the Schlemm's canal
22 Feb 22
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.
Kevin Peters
Filed: 28 Apr 20
Utility
Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
23 Nov 21
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
Kevin Peters, Michael Allen Flynn
Filed: 17 Apr 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first